Guideline Summary for Management of HCV‑Associated Thrombocytopenia

Diagnostic Confirmation

• Active HCV infection should be confirmed with quantitative HCV‑RNA testing (RT‑PCR), because a positive anti‑HCV antibody alone cannot differentiate current from past infection. 1
• Other causes of thrombocytopenia, especially immune thrombocytopenia (ITP), must be excluded; HCV infection itself can induce secondary ITP through immune‑mediated platelet destruction. 2

Primary Antiviral Therapy

• Eradicating HCV with direct‑acting antiviral (DAA) regimens resolves the underlying driver of thrombocytopenia; antiviral therapy is therefore the cornerstone of management. 3
• Interferon‑based regimens require close platelet monitoring because interferon can exacerbate thrombocytopenia by suppressing thrombopoietin production. 3

Safety Thresholds for Initiating Antiviral Therapy

• Patients with platelet counts > 100 × 10⁹/L can safely start DAA therapy without an increased risk of bleeding. 7
• Even when platelet counts are between 50 × 10⁹/L and 100 × 10⁹/L, treatment discontinuation due to thrombocytopenia is rare and major bleeding events do not increase. 7

Management of Thrombocytopenia During Treatment

• Thrombopoietin receptor agonists should not be used routinely for HCV‑associated thrombocytopenia because they do not improve sustained virologic response and increase the risk of portal vein thrombosis. 7
• If ITP becomes clinically significant (platelet < 30 × 10⁹/L with bleeding risk), a single‑dose intravenous immunoglobulin (IVIg) 1 g/kg is recommended as first‑line therapy. 3
• Corticosteroids are not recommended as first‑line agents for HCV‑related ITP; IVIg is preferred. 3

Common Pitfalls to Avoid

• Do not postpone antiviral therapy solely because of mild thrombocytopenia (e.g., platelets > 100 × 10⁹/L); treating HCV provides definitive resolution of the platelet abnormality. 3
• Never rely on anti‑HCV antibody positivity to infer active infection; always confirm with HCV‑RNA testing. 1
• Thrombopoietin agonists should not be given prophylactically, as they lack indication in this setting and carry thrombotic hazards. 7
• Thrombocytopenia, even with baseline counts < 50 × 10⁹/L, does not automatically contraindicate antiviral therapy; many patients can be treated safely. 7

Monitoring During Antiviral Therapy

• Platelet counts should be re‑checked at weeks 2, 4, 8, and 12 of DAA treatment to detect any clinically relevant decline. 7